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Geographic and temporal variation 
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2021 in the United States
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The coronavirus pandemic has disproportionally impacted racial and ethnic minority communities 
in the United States. Patterns of these disparities may be changing over time as outbreaks occur in 
different communities. Utilizing electronic health record data from the US Department of Veterans 
Affairs (VA), we estimated odds ratios, stratified by time period and region, for testing positive among 
1,313,402 individuals tested for SARS‑CoV‑2 between February 12, 2020 and August 16, 2021 at VA 
medical facilities. We adjusted for personal characteristics (sex, age, rural/urban residence, VA facility) 
and a wide range of clinical characteristics that have been evaluated in prior SARS‑CoV‑2 reports and 
could potentially explain racial/ethnic disparities in SARS‑CoV‑2. Our study found racial and ethnic 
disparities for testing positive were most pronounced at the beginning of the pandemic and decreased 
over time. A key finding was that the disparity among Hispanic individuals attenuated but remained 
elevated, while disparities among Asian individuals reversed by March 1, 2021. The variation in racial 
and ethnic disparities in SARS‑CoV‑2 positivity by time and region, independent of underlying health 
status and other demographic characteristics in a nationwide cohort, provides important insight for 
strategies to prevent further outbreaks.
The coronavirus pandemic has disproportionally impacted racial and ethnic minority communities in the United 
 States1–3. Evidence has highlighted the vast disparities in SARS-CoV-2 infection and subsequent COVID-19 
among persons who were Black, Hispanic or Latino, Native Hawaiian/Pacific Islander, American Indian/Alaska 
Native, or  Asian4–12. Recently, additional analyses have suggested that racial and ethnic disparities may be chang-
ing over time as outbreaks spread from racially and ethnically diverse metropolitan centers to more rural and 
less diverse  areas4,5,13,14. In this report, we updated our previous  analyses4,5 to evaluate changes in disparities for 
testing positive with SARS-CoV-2 over the first 18 months of the pandemic and by geographic region in the 
largest integrated healthcare system in the United States.
Methods
Utilizing national electronic health record data from the US Department of Veterans Affairs (VA), we conducted a 
retrospective cohort analysis of all Veterans tested for SARS-CoV-2 in VA medical facilities between February 12, 
2020 and August 16, 2021. Methods have been previously described in  detail4,5. In brief, SARS-CoV-2 tests were 
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identified using a text searching algorithm of laboratory results at VA for terms consistent with SARS-CoV-2 or 
COVID-19. For individuals with multiple tests, we selected the first positive test. For those without a positive test 
during the study period, we selected the first negative test. Analysis of test samples was performed in VA, state 
public health, and commercial laboratories using FDA Emergency Use Authorization-approved SARS-CoV-2 
assays. Nearly all the tests utilized nasopharyngeal swabs. We did not include antibody tests in this analysis.
We calculated the crude prevalence of testing positive for SARS-CoV-2 by time and race/ethnicity and 
calculated confidence intervals using the normal approximation. We used multivariable logistic regression to 
estimate odds ratios (OR) and 95% confidence intervals (CI) for testing positive for SARS-CoV-2 for Black, 
Hispanic or Latino (Hispanic), Asian, American Indian/Alaska Native, Native Hawaiian/Pacific Islander, and 
people of mixed race (Mixed), relative to White individuals. Race and ethnicity were self-reported. Individu-
als who reported Hispanic ethnicity were included in the Hispanic group regardless of any other self-reported 
race. A small proportion (4.0%) of individuals tested for SARS-CoV-2 with missing race/ethnicity information 
were excluded from analysis. All models were adjusted for other personal characteristics (sex, age, rural/urban 
residence) and a wide range of clinical characteristics that have been evaluated in prior SARS-CoV-2 reports 
and could potentially explain racial/ethnic disparities in SARS-CoV-2  positivity4,5,15,16. Clinical characteristics 
included baseline comorbidities (asthma, cancer, chronic kidney disease, chronic obstructive pulmonary disease, 
diabetes mellitus, hypertension, liver disease, vascular disease), substance use (alcohol consumption, alcohol use 
disorder, smoking status), medication history (angiotensin converting enzyme inhibitor, angiotensin II receptor 
blocker). Baseline for personal and clinical characteristics was defined as the date of specimen collection for the 
selected SARS-CoV-2 test. Models were additionally conditioned on VA site of care.
Models were a priori stratified into five waves based on the temporal distribution of SARS-CoV-2 cases 
nationally: February 12–May 31, 2020 (wave 1); June 1–September 30, 2020 (wave 2); October 1, 2020–February 
28, 2021 (wave 3); March 1, 2021–June 30, 2021 (wave 4); and July 1, 2021–August 16, 2021 (wave 5). Due to 
the large size of the third national wave, we split this period into two waves containing roughly equal numbers 
of SARS-CoV-2 cases (October 1–December 11, 2020 (wave 3a); and December 12, 2020–February 28, 2021 
(wave 3b).
To evaluate regional differences by time, models were further stratified by US Census region (i.e., West, South, 
Midwest, and Northeast). Odds ratios in strata by time and region with less than five cases were not reported 
due to potential privacy concerns and instability of statistical estimates. Data analysis was performed using SAS 
version 9.4 (SAS Institute, Cary, NC).
Ethics. This study was approved by the institutional review boards of VA Connecticut Healthcare System 
(VA AJ0013) and Yale University (1506016006). It has been granted a waiver of informed consent and is Health 
Insurance Portability and Accountability Act compliant.
Disclaimer. Views expressed are those of the authors and the contents of this article do not represent the 
views of the US Department of Veterans Affairs or the United States Government.
Results
Of 1,313,402 individuals tested for SARS-CoV-2 in the VA between February 2020 and August 2021, there were 
144,597 (11.0%) who tested positive for SARS-CoV-2 (Table 1). All non-White groups except for Asian individu-
als had higher crude prevalence of positive tests than White individuals (10.2%), with the largest differences 
observed among Black (12.2%), Hispanic (14.1%), and American Indian/Alaska Native (12.0.%) groups. By 
region, the crude prevalence of positive tests was highest in West (12.3%) and lowest in South (9.6%).
Individuals who were younger or male had a slightly higher crude prevalence of positive tests than those 
who were older or female. Over time, the prevalence of positive tests increased from 7.0% in wave 1, 6.3% in 
wave 2, 15.0% in wave 3a, and peaked at 20.5% in wave 3b. There was a marked decrease in the crude prevalence 
for positive tests in wave 4 to 5.8%, followed by a large increase to 16.2% in wave 5. In wave 1, all racial and 
ethnic minority groups had a higher unadjusted percentage of positive tests relative to White individuals, with 
the highest percentage observed among Black individuals at 12.0% (Fig. 1). In wave 3b, the highest percentage 
was observed among Hispanic individuals at 24.5%. By the end of wave 5, all racial and ethnic minority groups 
had a higher unadjusted percentage of positive tests relative to White individuals (15.2%), with the exception of 
Asian individuals who had the lowest at 12.9%. Over the study period, White individuals experienced the steep-
est increase in test positivity percentage (a 3.2-fold relative increase from 4.6% in wave 1 to 19.5% in the peak 
wave 3b and a 2.3-fold relative increase overall from 4.6% in wave 1 to 15.2% in wave 5) compared to increases 
observed in all other racial and ethnic minority groups.
After adjustment for personal and clinical characteristics, those who were Black (OR 1.18, 95% CI 1.17–1.20), 
Hispanic (1.42, 1.39–1.44), American Indian/Alaska Native (1.14, 1.07–1.21), or Native Hawaiian/Pacific Islander 
(1.13, 1.06–1.20) had elevated odds of testing positive, with no evidence of disparities among people of Mixed 
race (0.99, 0.94–1.05) compared to White individuals over the entire study period. Asian individuals had lower 
odds of testing positive compared to White individuals (0.90, 0.86–0.95) over the entire study period. However, 
there was substantial variation over time. Disparities for testing positive decreased for all racial and ethnic 
minorities over the study period (Fig. 2) with the largest disparities present in wave 1. In wave 1, disparities in 
test positivity were observed among Black (1.98, 1.87–2.11), Hispanic (1.87, 1.71–2.05), Asian (1.44, 1.12–1.84), 
and American Indian/Alaska Native (1.70, 1.25–2.32) individuals compared to White individuals. There was weak 
evidence of a disparity for testing positive among Native Hawaiian/Pacific Islander individuals (1.33, 0.97–1.83) 
and no observed disparity among people of mixed race (1.15, 0.89–1.50) in wave 1. By wave 3b, the peak of 
test positivity, disparities were not observed among any racial or ethnic minority group, apart from Hispanic 
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individuals (1.34, 1.29–1.40). A notable decrease in test positivity disparity was seen among Black individuals, 
from a near doubling of odds for testing positive in wave 1 (1.98, 1.87–2.11) to only marginally elevated odds by 
wave 3b (1.03, 1.00–1.06) compared to White individuals. There was a slight elevation in the odds among Black 
individuals for wave 4, but by wave 5 there was no observed dispairity in testing positive compared to White 
individuals. While Asian and American Indian/Alaska Native individuals had increased odds of testing positive 
in wave 1, this association attenuated rapidly and reversed for some. By the end of wave 4, Asian individuals had a 
33% lower odds of testing positive (0.67, 0.55–0.82) compared to White individuals, which persisted into wave 5.
We found some evidence of regional variation in the disparity for testing positive by time. While wave 1 dis-
parities for Black individuals were found in all regions, they were notably higher in the Midwest (2.72, 2.39–3.09) 
and the South (2.25, 2.03–2.50) compared with the Northeast (1.58, 1.41–1.76) and the West (1.30, 1.07, 1.58) 
(Fig. 3). Disparities for testing positive among Hispanic individuals were present in all regions across all time 
points, apart from wave 5. We found evidence of disparities for Asian individuals in wave 1 in the Northeast 
(1.79, 1.13–2.82) and Midwest (2.05, 1.03–4.09). American Indian/Alaska Native individuals had elevated odds 
of testing positive in the West in all time periods apart from wave 5, with the highest odds observed in wave 1 
(2.23, 1.36–3.66) (Fig. 4). There were no discernable patterns in regional disparities for Native Hawaiian/Pacific 
Islander individuals or those of Mixed race; however, these groups had relatively small numbers of events when 
stratified by time and region.
Discussion
Our nationwide study utilizing electronic health record data from the VA found that racial and ethnic disparities 
for testing positive for SARS-CoV-2 were most pronounced at the beginning of the pandemic and that these 
disparities decreased over time, even after accounting for a wide range of personal and clinical characteristics. 
By the end of the first 18 months of the pandemic, disparities for testing positive were attenuated but remained 
elevated for Hispanic individuals and were no longer observed for any other group. This attenuation in disparities 
appears to be due, at least in part, to a stronger relative increase in the test positivity percentage among White 
Table 1.  Characteristics of all individuals tested and tested positive for SARS-CoV-2 between February 12, 
2020 and August 16, 2021 in the US Department of Veterans Affairs (VA).
No. tested No. tested positive (row%)
Sample size 1,313,402 144,597 (11.0)
Race/ethnicity
White 846,678 86,164 (10.2)
Black 304,893 37,159 (12.2)
Hispanic 115,012 16,219 (14.1)
Asian 15,422 1519 (9.8)
American Indian/Alaska native 9120 1096 (12.0)
Native Hawaiian/Pacific islander 10,008 1125 (11.2)
Mixed 12,269 1315 (10.7)
Age, years
20–39 164,579 23,934 (14.5)
40–49 130,658 18,011 (13.8)
50–59 220,712 27,046 (12.3)
60–69 315,548 30,730 (9.7)
70–79 374,750 34,022 (9.1)
 ≥ 80 107,155 10,854 (10.1)
Sex
Female 143,523 15,369 (10.7)
Male 1,169,879 129,228 (11.0)
Region
West 262,898 32,441 (12.3)
South 159,668 15,324 (9.6)
Northeast 598,551 67,287 (11.2)
Midwest 292,285 29,545 (10.1)
Wave
1: February 12–May 31, 2020 114,584 7995 (7.0)
2: June 1–September 30, 2020 378,048 23,632 (6.3)
3a: October 1–December 11, 2020 261,912 39,372 (15.0)
3b: December 12, 2020–February 28, 2021 215,861 44,190 (20.5)
4: March 1–June 30, 2021 250,968 14,498 (5.8)
5: July 1–August 16, 2021 92,029 14,910 (16.2)
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individuals over time rather than a decline in test positivity among racial and ethnic minority groups, which 
may be driven by the pandemic generalizing from diverse metropolitan areas to less diverse rural areas and, for 
the later time periods, differential physical distancing practices, and differential vaccination uptake by race and 
 ethnicity4,5,13,14,17.
Our findings on disparities for testing positive among Black and Hispanic individuals in the first months of 
the pandemic have been demonstrated  previously1–5. This study extended previously published models to evalu-
ate patterns in disparities over the first full year and a half of the pandemic. A novel finding was that disparities 
for testing positive dramatically attenuated and were no longer observed by August 2021 among all racial and 
ethnic groups apart from Hispanic individuals. This disparity among Hispanic individuals was observed across 
all geographic regions between February 2020 and June 2021 and persisted after September 2020 most strongly 
in the West. A deeper understanding of the mechanism for this association is needed but may be due to the 
lack of nationwide media coverage and targeted, culturally-responsive, and language-accessible outreach and 
partnerships with Hispanic communities in the United States during that time. Hispanic individuals are also 
overrepresented in essential and frontline jobs, which increases their likelihood of SARS-CoV-2 exposure and 
they may face barriers (e.g., precarious employment or financial limitations) to taking sick leave that would help 
reduce the spread of SARS-CoV-218.
Another novel finding was the identification of increased odds of testing SARS-CoV-2 positive among Asian 
individuals in the first wave of the pandemic, which was obscured in the time-pooled model. We also found 
that Asian individuals had a lower odds of testing positive than White individuals between March and August 
2021. One hypothesis for the reduced odds of testing positive among Asian groups is the higher rate of vaccina-
tion among Asian individuals compared with White individuals which may account for their reduced odds of 
testing positive for SARS-CoV-2 in this  analysis17. An additional hypothesis is that SARS-CoV-2 cases among 
Asian individuals might be underreported to VA as Asian groups may experience differential barriers to care 
and have a lower likelihood of utilizing VA services, including getting tested at VA, than White  individuals5,10,19.
Our findings of racial and ethnic disparities for testing positive for SARS-CoV-2 provide important insight 
to help tailor strategies to contain and prevent further outbreaks in the United States. Early in the pandemic, 
tailored interventions to groups with higher risks may have been most effective. Now that the epidemic has 
generalized from large metropolitan centers with very high incidence to a more consistent rate of incidence 
across the country, racial and ethnic groups may be affected more equally suggesting that widescale prevention 
interventions for all persons may be most effective. However, the persistent disparities among Hispanic groups 
suggest that focused assessment and data-informed interventions in partnership with affected communities 
remains important in the effort to curtail infection hotspots, such as those due to a SARS-CoV-2 resurgence from 
the Delta and Omicron variants. SARS-CoV-2 is impacting all communities and is now much less concentrated 
in specific vulnerable groups compared to early in the pandemic. This does not imply that the overall cumulative 
burden of COVID-19 may be equal, as marginalized populations such as persons of color experienced substantial 
excess rates earlier in the epidemic and may experience excess extended effects or more severe outcomes from 
Figure 1.  Unadjusted race and ethnicity specific SARS-CoV-2 test positivity percentage by wave between 
February 12, 2020 and August 16, 2021 in the US Department of Veterans Affairs (VA). Notes: Wave 1 (February 
12–May 31, 2020); Wave 2 (June 1–September 30, 2020); Wave 3a (October 1–December 11, 2020); Wave 3b 
(December 12, 2020–February 28, 2021), Wave 4 (March 1–June 30, 2021; Wave 5 (July 1–August 16, 2021).
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Figure 2.  Adjusted racial and ethnic disparities in testing positive for SARS-CoV-2 between February 12, 
2020 and August 16, 2021, by wave of the pandemic in the US Department of Veterans Affairs (VA). Notes: 
Referent group for all comparisons is White. Model conditioned on site of care and adjusted for sex, age, rural/
urban residence, and baseline comorbidity (asthma, cancer, chronic kidney disease, chronic pulmonary disease, 
diabetes mellitus, hypertension, liver disease, vascular disease) substance use (alcohol consumption, alcohol use 
disorder, smoking status) , and medication history (angiotensin, converting enzyme inhibitor, angiotensin II 
receptor blocker). OR odd ratio, CI confidence interval.
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 infection20. Of note, access to free or subsidized care at VA has reduced the impact of negative social determinants 
of health on SARS-CoV-2 outcomes as prior reports found no racial or ethnic disparities in mortality among 
patients who tested positive for SARS-CoV-2 in the  VA4.
The VA electronic health record database offers the single largest nationwide data resource available in the 
United States with the required information on system-wide testing and detailed medical histories to examine 
Figure 3.  Adjusted racial and ethnic disparities in testing positive for SARS-CoV-2 between February 12, 
2020 and August 16, 2021 in the US Department of Veterans Affairs (VA), by US Census region among Black, 
Hispanic, and Asian individuals. Notes: Referent group for all comparisons is White. Strata with fewer than 
five positive cases are censored due to potential privacy concerns and instability of statistical estimates. Models 
conditioned on site of care and adjusted for sex, age, rural/urban residence, and baseline comorbidity (asthma, 
cancer, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, liver 
disease, vascular disease), substance use (alcohol consumption, alcohol use disorder, smoking status), and 
medication history (angiotensin converting enzyme inhibitor, angiotensin II receptor blocker). OR odds ratio, 
CI confidence interval.
Figure 4.  Adjusted racial and ethnic disparities in testing positive for SARS-CoV-2 between February 12, 
2020 and August 16, 2021 in the US Department of Veterans Affiars (VA), by US Census region among Mixed, 
Native Hawaiian/Pacific Islander, and American Indian/Alaska Native individuals. Notes: Referent group for all 
comparisons is White. Strata with fewer than five positive cases are censored due to potential privacy concerns 
and instability of statistical estimates. Models conditioned on site of care and adjusted for sex, age, rural/urban 
residence, and baseline comorbidity (asthma, cancer, chronic kidney disease, chronic obstructive pulmonary 
disease, diabetes mellitus, hypertension, liver disease, vascular disease), substance use (alcohol consumption, 
alcohol use disorder, smoking status), and medication history (angiotensin converting enzyme inhibitor, 
angiotensin II receptor blocker). OR odds ratio, CI confidence interval.
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racial and ethnic disparities. Our analysis identified time and regional variation in racial and ethnic disparities 
in SARS-CoV-2 positivity over the first 18 months of the pandemic independent of underlying health status 
and other key factors in a large, nationwide cohort. However, our analysis should be interpreted with some 
limitations, including those we previously described in  detail4,5. In brief, we only examined tests administered 
in VA; therefore, our results may not be representative of all Veterans tested for SARS-CoV-2. Second, although 
this population was primarily male, it included over 140,000 women. Third, as is the case with most electronic 
health record data sources, we did not have the necessary information to account for all social determinants of 
health (e.g., occupation or household details) in our analysis, which are critical to understanding and prevent-
ing health inequities, particularly in infectious disease outbreaks. Fourth, SARS-CoV-2 test availability varied 
by local case load, facility supply, and local policy, particularly in the first wave when non-Hispanic Black and 
Hispanic patients were more likely to receive a SARS-CoV-2 test than non-Hispanic White  patients12. However, 
after the first wave, testing was similar among all race and ethnic groups and test availability was unlikely to 
influence our results. Finally, while misclassified or missing data on race and ethnicity are often a concern, in this 
cohort, race and ethnicity were self-reported and there was a very small percentage with missing data. Focused 
research is needed to evaluate the association between social determinants of health and disparities seen during 
the COVID-19 pandemic as they may operate as confounders or may be on the causal pathway.
Data availability
Due to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic data sets 
used for this study are not permitted to leave the VA firewall without a Data Use Agreement. This limitation is 
consistent with other studies based on VA data. However, VA data are made freely available to researchers with 
an approved VA study protocol. For more information, please visit https:// www. virec. resea rch. va. gov or contact 
the VA Information Resource Center at VIReC@va.gov.
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